Showing 1291-1300 of 1319 results for "".
- Combined Lifestyle Interventions May Offset Alzheimer’s Disease Riskshttps://practicalneurology.com/news/combined-lifestyle-interventions-may-offset-alzheimers-disease-risks/2468957/Research findings reported at the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019 suggest that healthy lifestyle choices—including diet, exercise, and cognitive stimulation—may decrease risk of cognitive decline and dementia.
- Phase 3 Trial of Fenfluramine for Lennox-Gastaut Syndrome Completes Enrollmenthttps://practicalneurology.com/news/phase-3-trial-of-fenfluramine-for-lennox-gastaut-syndrome-completes-enrollment/2468948/Enrollment of 263 individuals with Lennox-Gastaut syndrome (LGS) has been completed for a phase 3 clinical (NCT03355209) trial of fenfluramine (Fintepla; Zogenix, Emeryville, CA). The primary outcome measure is decreased seizure freque
- Potential Treatment for Spinocerebellar Ataxia, CAD-1883, Granted Orphan Drug Statushttps://practicalneurology.com/news/potential-treatment-for-spinocerebellar-ataxia-cad-1883-granted-orphan-drug-status-1/2468913/The Food and Drug Administration (FDA) has granted orphan drug designation to CAD-1883 (Cadence Pharmaceuticals, San Diego, CA), an investigational treatment for spinocerebellar ataxia (SCA).The drug is also under investigation for treatment of essential tremor and other movement disorders.
- Opicapone Increases ON Time for Parkinson's Diseasehttps://practicalneurology.com/news/opicapone-increases-on-time-for-parkinsons-disease/2468886/In 2 phase 3 studies, treatment with opicapone (Neurocrine Biosciences, San Diego, CA) increased ON time without troublesome dyskinesia almost twice as much as placebo for participants with Parkinson’s disease (PD). The ON period was defined as the period during which motor symptoms are con
- Valbenazine Improvements for Tardive Dyskinesia Are Sustained in People Taking Different Neuropsychiatric Drugshttps://practicalneurology.com/news/valbenazine-improvements-for-tardive-dyskinesia-are-sustained-in-people-taking-different-neuropsychiatric-drugs/2468885/Pooled data analysis from 2 phase 3 trials shows that valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), approved for treatment of tardive dyskinesia (TD) in adults, has sustained efficacy whether or not other neuropsychiatric drugs are taken concomitantly. The efficacy and safety of
- Minimally Invasive Removal of Deep Subcortical Hemorrhagehttps://practicalneurology.com/news/minimally-invasive-removal-of-deep-subcortical-hemorrhage/2468770/Minimally invasive techniques have been used to treat deep subcortical hemorrhages successfully. In 2 abstracts, presented at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in San Diego, CA, minimally invasive parafascicular surgery (MIPS) with tubular retracto
- Blood Test for TBI Licensed for Use and Development on Abbot Laboratory Instrumentshttps://practicalneurology.com/news/blood-test-for-tbi-licensed-for-use-and-develoment-on-abbot-laboratory-instruments/2468773/A Food and Drug Administration (FDA) approved blood test for mild traumatic brain injury (mTBI), also known as concussion, may become more widely available soon. The blood test (Banyan Brain Trauma Indicator; Banyan Biomarkers, San Diego, CA) has been licensed to Abbott Laboratories (Abbott Park,
- Trofinetide Phase 2 Study Shows Safety and Clinically Relevant Improvement for Rett's Syndromehttps://practicalneurology.com/news/trofinetide-phase-2-study-shows-safety-and-clinically-relevant-improvement-for-retts-syndrome/2468790/Positive results from a phase 2 randomized, placebo-controlled clinical trial (NCT02715115) of trofinetide (Acadia Pharmaceuticals, San Diego, CA; Neuren Pharmaceuticals, Melbourne, Australia; and Rettsyndrome.org, Cincinnati, OH) for
- Valbenazine Reduces Involuntary Movements in Patients with Mood Disordershttps://practicalneurology.com/news/valbenazine-reduces-involuntary-movements-in-patients-with-mood-disorders/2468867/A post-hoc analysis of data from a clinical trial of valbenazine (Ingrezza; Neurocrine Biosciences, Inc., San Diego, CA) has been published in the Journal of Affective Disorders. This analysis showed sustained improvement in tardive dyskinesia (TD) symptoms in patients with primary
- Peter McAllister, MDhttps://practicalneurology.com/profiles/peter-mcallister-md/7ZXW1w/Peter is a board certified neurologist and Director of the New England Center for Neurology and Headache, where he sees adults and children (age five and over) and employs a holistic, biopsychosocial approach to diagnosis and treatment . Formerly Director of the Headache Center, Concussion Center a…